Trial Profile
Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease (E-HART)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms E-HART
- 15 May 2019 Planned End Date changed from 1 Nov 2019 to 15 May 2019.
- 15 May 2019 Planned primary completion date changed from 1 Nov 2019 to 15 May 2019.
- 15 May 2019 Planned initiation date changed from 1 Mar 2017 to 3 Apr 2017.